Last reviewed · How we verify

Elocon (MOMETASONE FUROATE)

Merck & Co. · FDA-approved approved Small molecule Verified Quality 75/100

Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body.

Elocon (MOMETASONE FUROATE) is a corticosteroid medication originally developed by Merck Sharp Dohme and currently owned by Organon. It targets the progesterone receptor and is a small molecule modality. Elocon is FDA-approved for various allergic and inflammatory conditions, including allergic rhinitis, asthma, and atopic dermatitis. The medication is off-patent, with 15 generic manufacturers available. Key safety considerations include its low bioavailability and short half-life.

At a glance

Generic nameMOMETASONE FUROATE
SponsorMerck & Co.
Drug classCorticosteroid
TargetProgesterone receptor
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval1987

Mechanism of action

NASONEX Nasal Spray 50 mcg is corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.In two clinical studies utilizing nasal antigen challenge, NASONEX Nasal Spray, 50 mcg decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known.The effect of NASONEX Nasal Spray, 50 mcg on nasal mucosa following 12 months of treatment was examined in 46 patients w

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType
80256352027-06-12Formulation
102321522034-11-24Formulation
103576402031-10-03Method of Use
95856812026-04-04Method of Use
75441922026-11-29Method of Use
104063322034-03-13Formulation
87632222032-02-08Formulation

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: